Aurinia Pharmaceuticals Inc. Overview
Pro stress-test →Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company's lead commercial product is LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, a severe complication of systemic lupus erythematosus. Total revenue reached $283.1 million for 2025, up 20% from 2024, with LUPKYNIS net product sales rising 25% to $271.3 million.
Strategic Profile
Pro stress-test →The company moved to solid profitability, with 2025 net income of $287.2 million versus $5.8 million a year earlier. A collaboration with Otsuka Pharmaceutical Co., Ltd. has allowed Aurinia to extend its market presence to Japan, the E.U., the U.K., and Switzerland, diversifying revenue streams and mitigating single-market risk. However, Aurinia's dependence on LUPKYNIS for the majority of its revenue exposes the company to market volatility and competitive pressures, as any challenges could have a disproportionate impact on financial performance.
Competitive Landscape
Pro stress-test →LUPKYNIS is the first FDA-approved oral therapy for active lupus nephritis. Aurinia competes in the specialty immunosuppressant and lupus nephritis treatment space against traditional therapies and other biopharmaceutical companies. The first-mover advantage in oral lupus nephritis treatment provides differentiation, though competitive threats from other autoimmune disease therapies exist.
Industry Context
Aurinia Pharmaceuticals Inc. operates in Biopharmaceutical / Specialty Pharmaceuticals.
Key facts
Founded: 1993 · Headquarters: Edmonton, Canada · Revenue: $283.1M (2025) · Market cap: $1.9B